Pulmonx Corp SEC Filings

A shareholder of LUNG has filed a notice of proposed sale under Rule 144 to sell 31,082 common shares through Morgan Stanley Smith Barney LLC. The filing lists an aggregate market value of 62,073.62 for these shares, with an approximate sale date of January 14, 2026 on NASDAQ. The notice also shows that 41,247,034 common shares are outstanding and that the shares to be sold were acquired via restricted stock, open market purchases, and an employee stock purchase plan.

Pulmonx Corp reported new equity awards to its Chief Operating Officer and Chief Financial Officer on December 1, 2025. The executive received 1,200,000 Restricted Stock Units that are payable in common stock. According to the terms, 25% of these units vest one year after the grant date, with the remaining balance vesting in equal quarterly installments over the following three years.

The executive also received 400,000 Performance Stock Units, each tied to one share of common stock. These units vest only if two conditions are met: the company’s stock reaches a specified price per share and time-based milestones are satisfied, with 33% vesting one year after the grant date and the rest in eight equal quarterly installments through December 1, 2028. Both awards are shown at a price of $0, reflecting that they are equity incentives rather than open-market purchases.

Pulmonx Corporation has filed an amended shelf registration statement on Form S-3 that allows it to offer and sell up to an aggregate of $200,000,000 of securities over time. The company may issue common stock, preferred stock, debt securities and warrants, either individually or in combination, and may also issue common or preferred stock or debt upon conversion or exercise of these instruments. Specific terms such as pricing, maturity, interest or dividend features, and underwriting arrangements will be set in future prospectus supplements for each offering. Pulmonx states that, unless otherwise described in a supplement, net proceeds will be used for working capital, research and development, capital expenditures and other general corporate purposes. The filing highlights that investing in its securities involves a high degree of risk and directs investors to detailed risk factors in its Annual and Quarterly Reports.

Pulmonx Corporation filed a Form S-8 to register 3,200,000 shares of common stock for issuance under its new 2025 Inducement Plan. The board adopted this plan on November 21, 2025 to grant equity-based awards to new employees as an inducement to join the company, in line with Nasdaq Listing Rule 5635(c)(4). The plan was approved by the Compensation Committee without stockholder approval, as that rule allows for inducement grants. The filing also restates that Pulmonx indemnifies its directors and executive officers to the fullest extent permitted by Delaware law and maintains directors’ and officers’ liability insurance.

Pulmonx Corporation (LUNG) reported insider ownership via a Form 3. Executive Derrick Sung, who serves as COO and CFO, disclosed 135,319 shares of Common Stock held directly. The filing lists the Date of Event as 11/03/2025. No derivative securities were reported in Table II.

Pulmonx (LUNG) announced leadership changes and compensation terms. Steven S. Williamson resigned as President, CEO, and director effective October 27, 2025. He will receive $600,000 over 12 months and COBRA reimbursement for up to 14 months, and will consult through December 1, 2025 for a $50,000 fee with continued equity vesting until that date.

The Board appointed Glendon E. French as President and CEO effective October 27, 2025, continuing as a Class I director. His offer includes a $625,000 base salary, a target bonus equal to 100% of salary, a 1,200,000-share RSU grant vesting quarterly over three years, and an 800,000-share PSU grant that vests upon time-based milestones and a performance condition of a $4.00 average closing price over 60 consecutive trading days.

Mehul Joshi resigned as CFO effective October 27, 2025 and will receive $347,625 over nine months, COBRA reimbursement up to 11 months, and a $30,000 consulting fee with equity vesting through December 1, 2025. Derrick Sung, Ph.D., was appointed COO and CFO effective November 3, 2025, with a $500,000 base salary, a 60% target bonus, a 1,200,000-share RSU, and a 400,000-share PSU with the same $4.00 performance condition.

Pulmonx Corporation is filing an S-3 shelf registration that incorporates recent SEC reports and exhibits and references its commercial and regulatory position for key products. The Zephyr Valve is commercially available in numerous countries and included in COPD treatment guidelines; the company references a pre-market approval (PMA) pathway related to a Breakthrough Device designation. The AeriSeal System holds a Breakthrough Device designation in the U.S., a Certificate of Conformity in Europe, is not FDA approved for U.S. commercial sale and is in a global clinical trial called CONVERT II to support a PMA application. The filing lists incorporated documents including Form 10-K, multiple 10-Qs, an 8-A and exhibits, and shows a reported amount of $22,040 in a table. Several exhibit and filing dates are provided, including corporate charter and bylaws references and counsel/accounting consents.

FMR LLC and Abigail P. Johnson report beneficial ownership of 2,179,993.02 shares of Pulmonx Corp common stock, representing 5.4% of the outstanding class. FMR LLC is shown with sole voting power over 2,175,878 shares and sole dispositive power over 2,179,993.02 shares; Abigail P. Johnson is reported with sole dispositive power over 2,179,993.02 shares and no voting power. The filing states the shares are held in the ordinary course of business and were not acquired to change or influence control of the issuer.

The filing refers to an accompanying Exhibit 99 and incorporates prior powers of attorney by reference. No other person is identified as holding more than 5% of the common stock.